Clinical Rhinology

Register      Login

VOLUME 5 , ISSUE 2 ( May-August, 2012 ) > List of Articles


Invasive Fungal Sinusitis

Rijuneeta, Bhumika Gupta

Keywords : Rhinosinusitis,Fungal sinusitis,Invasive,Nose and paranasal sinuses

Citation Information : R, Gupta B. Invasive Fungal Sinusitis. Clin Rhinol An Int J 2012; 5 (2):63-71.

DOI: 10.5005/jp-journals-10013-1123

Published Online: 01-08-2012

Copyright Statement:  Copyright © 2012; The Author(s).


How to cite this article

Gupta AK, Bansal S, Rijuneeta, Gupta B. Invasive Fungal Sinusitis. Clin Rhinol An Int J 2012;5(2): 63-71.

PDF Share
  1. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: Clinical spectrum and outcome in 25 cases. Neurosurgery 2004;55:602-11.
  2. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803.
  3. Definition of fungal rhinosinusitis. Otolaryngol Clin North Am 2000;33:227.
  4. Practice guidelines for disease caused by Aspergillus. Clinical Infectious Dis 2000;30:696-709.
  5. Fungal sinusitis. N Engl J Med 1997;337:254-59.
  6. A new classification and diagnostic criteria for invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 1997;123(11):1181-88.
  7. Fungal sinusitis. Am J Med Sci 1998;316(1): 39-45.
  8. Chronic invasive fungal rhinosinusitis. Otolaryngol Clin North Am 2000;33(2):375-87.
  9. N Engl J Med 2009;360:1870-84.
  10. Invasive aspergillosis: Disease spectrum, treatment practices and outcomes. I3 aspergillus Study Group. Medicine 2000;79: 250-60.
  11. In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 1998; 42:91-94.
  12. In vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998; 42:389-92.
  13. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998;42:531-33.
  14. Activity of voriconazole (UK-109, 496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1997;41:696-98.
  15. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man [abstract F78]. In program and abstract of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American society or Microbiology 1995:126.
  16. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
  17. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
  18. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31.
  19. Fulminant aspergillosis of the nose and paranasal sinuses: A new clinical entity. Laryngoscope 1980;90:748-54.
  20. Percivall Pott: An 18th century neurosurgeon. J Neurosurg 1992;76(2):319-26.
  21. Intracranial complications of sinusitis. Laryngoscope 1997;107(7):863-67.
  22. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am 2000;33(2):323-34.
  23. Invasive fungal sinusitis of isolated sphenoid sinus in immunocompetent subjects. Mycoses 2006;49(1):30-36.
  24. Pediatric invasive fungal rhinosinusitis in immunocompromised children with cancer. Otolaryngol Head Neck Surg 2005;133(3):411-16.
  25. Computed tomographic findings in patients with invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 2003;129(2):236-40.
  26. Periantral soft-tissue infiltration and its relevance to the early detection of invasive fungal sinusitis: CT and MR findings. Am J Neuroradiol 1998;19(2): 321-25.
  27. Histopathology of fungal rhinosinusitis. Otolaryngol Clin North Am 2000;33(2):251-76.
  28. Impact of surgical treatment on paranasal fungal infections in bone marrow transplant patients. Otolaryngol Head Neck Surg 1997;116: 610-16.
  29. Invasive fungal sinusitis: A 15-year review from a single institution. Am J Rhinol 2004;18(2):75-81.
  30. Invasive sinus aspergillosis in apparently immunocompetent hosts. J Infect 1998;37:229-40.
  31. Fungal rhinosinusitis: A categorization and definitional schema addressing current controversies. Laryngoscope 2009;119(9):1809-18.
  32. Rhinocerebral aspergillosis. J Laryngol Otol 1992;106:981-85.
  33. Chronic invasive aspergillosis of the paranasal sinuses in immunocompetent hosts from Saudi Arabia. Am J Trop Med Hyg 2001;65:83-86.
  34. Intracranial invasive aspergillosis; can a combined modality approach result in superior patient outcome?. Clin Rhinol 2008;1(1):1-5.
  35. Chronic fungal sinusitis in apparently normal hosts. Medicine 1988;67:231-47.
  36. Aspergillus flavus: Human pathogen, allergen and mycotoxin producer. Microbiology 2007;153:1677-92.
  37. Aspergillus fumigatus: Principles of pathogenesis and host defense. Eukaryot Cell 2007;6:1953-63.
  38. Density and molecular epidemiology of aspergillus in air and relationship to outbreaks of aspergillus infection. J Clin Microbiol 1999; 37:1752-57.
  39. Census of aspergillus colonies in the air comparison between London, Paris, Lyon, Marseilles. Acta Allergol 1972;27:273-78.
  40. Variations in fungal spores in the air during the last 10 years in belgium. Bull Mem Acad R Med Belg 1985;140:147-48.
  41. Prevalence of airborne Aspergillus flavus in khartoum (Sudan) airspora with reference to dusty weather and inoculum survival in simulated summer conditions. Mycopathologia 1988;104:137-41.
  42. Airborne viable, non-viable, and allergenic fungi in a rural agricultural area of India: A 2-year study at five outdoor sampling stations. Sci Total Environ 2004;326:123-41.
  43. Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease. Trans Am Clin Climatol Assoc 2007; 118:175-85.
  44. Effects of the Aspergillus fumigatus siderophore systems on the regulation of macrophage immune effector pathways and iron homeostasis. Immunobiology 2008;213:767-78.
  45. Chronic invasive sinus aspergillosis in immunocompetent hosts: A geographic comparison. Mycopathologia 2010;170(6):403-10.
  46. Postoperative responses of paranasal Aspergillus granuloma to itraconazole. Trans R Soc Trop Med Hyg 1992;86:93-94.
  47. Nasosinusal fungal granuloma-clinical profile. Singapore Med J 1996;37:470-74.
  48. Continual intracavitary administration of Amphotericin B as an adjunct in the treatment of Aspergillus brain abscess: Case report and review of the literature. Neurosurgery 1992;31:575-79.
  49. Successful treatment of Invasive sinusitis with caspofungin and voriconazole. Ear Nose Throat J 2008;87:30-33.
  50. Invasive sphenoidal aspergillosis: Successful treatment with sphenoidotomy and voriconazole. ORL J Otorhinol Relat Spec 2007;68:121-26.
  51. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006;49(Suppl 1):37-41.
  52. Should Voriconazole be the primary therapy for Chronic invasive Sinus Aspergillosis. Clinical Rhinology: An International Journal 2011; 4(1): 21-26.
  53. Rhinocerebral aspergillosis in patients undergoing bone marrow transplantation. Ann Otol Rhinol Laryngol 1994;103:306-10.
  54. Rhinocerebral aspergillosis. Otolaryngol Head Neck Surg 1998;119:554-55.
  55. Antifungal and surgical treatment of invasive aspergillosis: Review of 2121 published cases. Rev Infect Dis 1990; 12:1147-201.
  56. Aspergillosis case fatality rate: systemic review of the literature. Clin Infect Dis 2001;32: 358-66.
  57. The impact of culture isolation of Aspergillus species: Hospital-based survey of aspergillosis. Clin Infect Dis 2001;33:1824-33.
  58. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.